A Study to Assess the Impact of Omalizumab on Exercise Capacity, Physical Activity, and Sleep Quality in Participants With Moderate to Severe Allergic Asthma

NCT04195958 · clinicaltrials.gov ↗

PHASE4

Phase

TERMINATED

Status

3

Enrollment

INDUSTRY

Sponsor class

Stopped Due to low enrollment, this study was terminated early.

Conditions

Moderate-to-severe Allergic Asthma

Interventions

DRUG: Omalizumab

Sponsor

Genentech, Inc.